- Home
- VEEE vs KZIA Comparison
VEEE vs KZIA Comparison
Compare VEEE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEE
- KZIA
- Stock Information
- Founded
- VEEE 1994
- KZIA 1994
- Country
- VEEE United States
- KZIA Australia
- Employees
- VEEE 65
- KZIA N/A
- Industry
- VEEE Marine Transportation
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- VEEE Industrials
- KZIA Health Care
- Exchange
- VEEE Nasdaq
- KZIA Nasdaq
- Market Cap
- VEEE 5.1M
- KZIA 5.1M
- IPO Year
- VEEE 2021
- KZIA 1999
- Fundamental
- Price
- VEEE $2.33
- KZIA $9.76
- Analyst Decision
- VEEE
- KZIA Strong Buy
- Analyst Count
- VEEE 0
- KZIA 2
- Target Price
- VEEE N/A
- KZIA $14.00
- AVG Volume (30 Days)
- VEEE 54.1K
- KZIA 671.8K
- Earning Date
- VEEE 08-13-2025
- KZIA 07-29-2025
- Dividend Yield
- VEEE N/A
- KZIA N/A
- EPS Growth
- VEEE N/A
- KZIA N/A
- EPS
- VEEE N/A
- KZIA N/A
- Revenue
- VEEE $12,724,465.00
- KZIA $1,549,158.00
- Revenue This Year
- VEEE N/A
- KZIA N/A
- Revenue Next Year
- VEEE N/A
- KZIA N/A
- P/E Ratio
- VEEE N/A
- KZIA N/A
- Revenue Growth
- VEEE N/A
- KZIA 248983.08
- 52 Week Low
- VEEE $2.05
- KZIA $2.86
- 52 Week High
- VEEE $9.30
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- VEEE 55.03
- KZIA 63.36
- Support Level
- VEEE $2.21
- KZIA $9.59
- Resistance Level
- VEEE $2.40
- KZIA $12.00
- Average True Range (ATR)
- VEEE 0.09
- KZIA 1.12
- MACD
- VEEE 0.04
- KZIA 0.16
- Stochastic Oscillator
- VEEE 100.00
- KZIA 68.03
About VEEE Twin Vee PowerCats Co.
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.